The maintenance of tumour vasculature appears to involve CXCR4 activity, with CXCR4 antagonists reducing GSC production of VEGF, tumour cells’ ability to mimic vascular structures and the number of CD31+ or VEGF+ cells intratumourally [120,121,125]. This evidence concerns the gene CXCR4 and neoplasm.